| 2025-08-04 | +24.9% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2025-08-05 | +23.9% | news | Seeking Alpha | Syndax Pharmaceuticals: The Story Brightens (NASDAQ:SNDX) - Seeking Alpha |
| 2025-08-05 | +23.9% | news | simplywall.st | Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt? - simplywall.st |
| 2025-08-05 | +23.9% | analyst | GuruFocus | SNDX: Citigroup Boosts Price Target Amid Buy Rating | SNDX Stock News - GuruFocus |
| 2024-11-12 | -23.4% | legal | SEC EDGAR | SNDX 8-K: 8.01 and (SEC Filing) |
| 2025-05-05 | -21.1% | legal | SEC EDGAR | SNDX 8-K: 2.02, 8.01 (SEC Filing) |
| 2021-05-11 | +17.6% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2025-08-14 | +17.3% | earnings | Yahoo Finance | Syndax Pharmaceuticals (SNDX) Is Up 15.8% After Revenue Surges in Q2 2025 Results Has Sentiment Shifted? - Yahoo Finance |
| 2025-11-10 | +16.1% | news | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript |
| 2021-12-17 | +15.0% | legal | SEC EDGAR | SNDX 8-K: 1.01 and (SEC Filing) |
| 2022-12-07 | -13.6% | legal | SEC EDGAR | SNDX 8-K: 1.01 and (SEC Filing) |
| 2025-08-13 | +13.2% | expansion | Seeking Alpha | Syndax Pharmaceuticals: A Tale Of Two Drug Launches (NASDAQ:SNDX) - Seeking Alpha |
| 2025-11-03 | +13.0% | earnings | Seeking Alpha | Syndax Pharmaceuticals GAAP EPS of -$0.70 beats by $0.04, revenue of $45.9M misses by $2.07M |
| 2025-11-03 | +13.0% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2025-11-03 | +13.0% | earnings | Yahoo Finance | Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance |
| 2025-10-24 | -12.7% | legal | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - Slideshow |
| 2025-10-24 | -12.7% | news | Seeking Alpha | Syndax gains additional indication for Revuforj in acute myeloid leukemia |
| 2025-10-24 | -12.7% | legal | SEC EDGAR | SNDX 8-K: 8.01 and (SEC Filing) |
| 2025-10-24 | -12.7% | news | Benzinga | Why Is Syndax Stock Down Today? - Syndax Pharmaceuticals (NASDAQ:SNDX) - Benzinga |
| 2025-10-24 | -12.7% | legal | Stock Titan | Syndax (NASDAQ: SNDX) wins FDA approval as Revuforj first for R/R NPM1 AML, KMT2A leukemia - Stock Titan |
| 2025-10-24 | -12.7% | legal | Stocktwits | SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval - Stocktwits |
| 2025-11-23 | +11.8% | news | simplywall.st | Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up - simplywall.st |
| 2023-10-02 | -11.6% | legal | SEC EDGAR | SNDX 8-K: 8.01 and (SEC Filing) |
| 2026-03-06 | +11.1% | news | DirectorsTalk Interviews | Syndax Pharmaceuticals (SNDX) Stock Analysis: A Biotech With 76.51% Upside Potential - DirectorsTalk Interviews |
| 2026-04-22 | -10.6% | news | TipRanks | Why Syndax Pharmaceuticals Stock Is Sinking Today - TipRanks |
| 2025-11-04 | +10.6% | earnings | Seeking Alpha | Syndax targets $10B market as Revuforj gains NPM1 approval and Q3 revenue rises 21% |
| 2025-11-04 | +10.6% | earnings | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Q3 2025 Earnings Call Transcript |
| 2025-11-04 | +10.6% | legal | Yahoo Finance | Syndax Pharmaceuticals (SNDX) Is Up 13.6% After FDA Approval Expands Revuforj Use in AML - Yahoo Finance |
| 2021-12-13 | +9.1% | legal | SEC EDGAR | SNDX 8-K: 8.01 and (SEC Filing) |
| 2024-11-05 | +9.0% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2026-03-09 | +8.8% | news | Investing.com | Syndax Pharmaceuticals stock hits 52-week high at $22.91 - Investing.com |
| 2026-03-09 | +8.8% | analyst | 24/7 Wall St. | uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - 24/7 Wall St. |
| 2021-12-09 | -8.5% | legal | SEC EDGAR | SNDX 8-K: 8.01 and (SEC Filing) |
| 2021-10-04 | -8.3% | legal | SEC EDGAR | SNDX 8-K: 5.02 and (SEC Filing) |
| 2023-05-08 | +8.2% | legal | SEC EDGAR | SNDX 8-K: 2.02, 5.02 (SEC Filing) |
| 2026-02-27 | +7.5% | news | Seeking Alpha | Syndax signals expanding Revuforj market share and targets $10B addressable opportunity while ramping Niktimvo |
| 2026-02-27 | +7.5% | earnings | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript |
| 2026-02-27 | +7.5% | news | Yahoo Finance | Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? - Yahoo Finance |
| 2026-02-27 | +7.5% | analyst | Investing.com | Stifel raises Syndax Pharmaceuticals stock price target on drug sales - Investing.com |
| 2026-02-27 | +7.5% | earnings | The Globe and Mail | Syndax (SNDX) Q4 2025 Earnings Call Transcript - The Globe and Mail |
| 2026-03-27 | -7.0% | analyst | Investing.com | Jefferies cuts Syndax Pharmaceuticals stock price target on valuation - Investing.com |
| 2021-08-09 | +6.9% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2026-04-01 | +6.8% | earnings | MarketBeat | Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Assenagon Asset Management S.A. - MarketBeat |
| 2026-04-01 | +6.8% | earnings | MarketBeat | Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - MarketBeat |
| 2026-04-01 | +6.8% | analyst | 富途牛牛 | Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛 |
| 2024-03-18 | -6.7% | legal | SEC EDGAR | SNDX 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-08-12 | +6.1% | earnings | Yahoo Finance | FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals - Yahoo Finance |
| 2021-09-27 | +6.1% | legal | SEC EDGAR | SNDX 8-K: 1.01, 7.01 (SEC Filing) |
| 2024-05-08 | -5.8% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2026-01-05 | -5.8% | executive | Quiver Quantitative | Syndax Pharmaceuticals CEO to Present at 44th Annual J.P. Morgan Healthcare Conference | SNDX Stock News - Quiver Quantitative |
| 2026-02-26 | +5.7% | earnings | Seeking Alpha | Syndax Pharmaceuticals GAAP EPS of -$0.78 misses by $0.23, revenue of $68.7M beats by $3.95M |
| 2026-02-26 | +5.7% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | +5.7% | earnings | Yahoo Finance | Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance |
| 2026-02-26 | +5.7% | earnings | GuruFocus | Syndax Pharmaceuticals (SNDX) Reports Strong 2025 Earnings and G - GuruFocus |
| 2026-02-26 | +5.7% | earnings | MarketBeat | Syndax Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat |
| 2025-07-08 | +5.3% | news | Seeking Alpha | Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals - Seeking Alpha |
| 2025-03-03 | -5.1% | legal | SEC EDGAR | SNDX 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-11-17 | +4.6% | earnings | Yahoo Finance | Syndax Pharmaceuticals (SNDX): Assessing Value After Revuforj FDA Expansion and Revenue Surge - Yahoo Finance |
| 2024-05-15 | -4.4% | legal | SEC EDGAR | SNDX 8-K: 5.02, 5.07, 7.01 (SEC Filing) |
| 2025-11-12 | -4.4% | analyst | Investor's Business Daily | Syndax Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily |
| 2025-09-07 | -4.4% | earnings | simplywall.st | When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Turn A Profit? - simplywall.st |
| 2025-10-26 | -4.3% | news | Seeking Alpha | Syndax Expands Revuforj Approval (NASDAQ:SNDX) - Seeking Alpha |
| 2025-10-25 | -4.3% | legal | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript |
| 2025-10-25 | -4.3% | legal | Yahoo Finance | Syndax Pharmaceuticals (SNDX): Valuation in Focus After FDA Approval of Revuforj for NPM1-Mutated AML - Yahoo Finance |
| 2026-02-12 | -4.2% | expansion | Seeking Alpha | Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 |
| 2026-02-12 | -4.2% | expansion | Seeking Alpha | Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX) - Seeking Alpha |
| 2026-01-13 | +4.2% | news | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow |
| 2026-01-13 | +4.2% | news | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-13 | +4.2% | news | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha |
| 2026-03-25 | +4.1% | news | TipRanks | Why Syndax Pharmaceuticals Stock Is Suddenly Surging - TipRanks |
| 2024-08-01 | -4.1% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2026-02-13 | -4.0% | earnings | Yahoo Finance | BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact - Yahoo Finance |
| 2026-02-13 | -4.0% | news | simplywall.st | Have Insiders Sold Syndax Pharmaceuticals Shares Recently? - simplywall.st |
| 2023-03-30 | -4.0% | legal | SEC EDGAR | SNDX 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-04 | -3.9% | earnings | MarketBeat | SG Americas Securities LLC Has $2.72 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat |
| 2026-04-03 | -3.9% | news | GlobeNewswire | Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2026-04-03 | -3.9% | news | Seeking Alpha | Most and least shorted mid-to mega-cap healthcare stocks in March |
| 2026-04-03 | -3.9% | news | ChartMill | Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - ChartMill |
| 2025-12-08 | -3.6% | news | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript |
| 2025-11-05 | -3.6% | news | Seeking Alpha | Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026 |
| 2025-11-05 | -3.6% | news | Seeking Alpha | Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026 (SNDX) - Seeking Alpha |
| 2025-12-12 | +3.5% | news | Stock Traders Daily | (SNDX) Movement as an Input in Quant Signal Sets - Stock Traders Daily |
| 2026-04-23 | -3.5% | earnings | MarketBeat | Torray Investment Partners LLC Invests $2.06 Million in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat |
| 2026-04-23 | -3.5% | news | Stock Traders Daily | (SNDX) Movement as an Input in Quant Signal Sets - Stock Traders Daily |
| 2023-11-02 | +3.5% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2026-02-04 | -3.4% | analyst | Investing.com | Syndax stock maintains momentum as B.Riley reiterates Buy rating - Investing.com |
| 2026-02-04 | -3.4% | news | Stock Titan | New hires at cancer drug maker Syndax get 11,600 stock options - Stock Titan |
| 2023-05-26 | -3.4% | legal | SEC EDGAR | SNDX 8-K: 1.02, 8.01 (SEC Filing) |
| 2025-05-16 | +3.2% | legal | SEC EDGAR | SNDX 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-03-30 | -3.1% | analyst | Investing.com | Mizuho lowers Syndax Pharmaceuticals stock price target on sales timing - Investing.com |
| 2026-03-30 | -3.1% | earnings | MarketBeat | Jefferies Financial Group Reiterates "Buy" Rating for Syndax Pharmaceuticals (NASDAQ:SNDX) - MarketBeat |
| 2022-02-03 | -3.1% | legal | SEC EDGAR | SNDX 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-11-30 | -3.1% | news | Seeking Alpha | Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth |
| 2025-11-29 | -3.1% | news | Seeking Alpha | Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth - Seeking Alpha |
| 2022-03-01 | +3.0% | legal | SEC EDGAR | SNDX 8-K: 2.02, 5.02, 7.01 (SEC Filing) |
| 2026-04-10 | -3.0% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Syndax Pharmaceuticals (SNDX) Stock a future winner | Price at $24.32, Down 1.80% - Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Lào Cai |
| 2022-05-09 | -2.9% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2026-04-20 | -2.9% | analyst | 富途牛牛 | Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛 |
| 2023-08-03 | -2.8% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2026-02-06 | +2.8% | executive | Investing.com | Syndax Pharmaceuticals CEO sells $152,835 in SNDX stock - Investing.com |
| 2024-11-04 | +2.7% | legal | SEC EDGAR | SNDX 8-K: 1.01 (SEC Filing) |
| 2026-02-10 | +2.7% | executive | Investing.com | Syndax Pharma CFO Goldan sells $71k in shares - Investing.com |
| 2026-02-10 | +2.7% | executive | Investing.com | Syndax Pharmaceuticals CEO Metzger sells $360k in stock - Investing.com |
| 2026-04-08 | -2.7% | earnings | MarketBeat | Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 52-Week High - Should You Buy? - MarketBeat |
| 2026-04-08 | -2.7% | earnings | MarketBeat | Palumbo Wealth Management LLC Invests $1.08 Million in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat |
| 2026-03-10 | +2.6% | news | Stock Traders Daily | Avoiding Lag: Real-Time Signals in (SNDX) Movement - Stock Traders Daily |
| 2025-12-09 | +2.6% | news | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting - Slideshow |
| 2025-12-09 | +2.6% | analyst | Investing.com | Syndax stock maintains Buy rating as Revuforj shows real-world success - Investing.com |
| 2026-03-18 | +2.6% | news | Simply Wall St. | Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge? |
| 2026-03-18 | +2.6% | expansion | Seeking Alpha | Syndax Pharma: Two Drug Launches Fuel Transformational Growth |
| 2026-03-18 | +2.6% | expansion | Seeking Alpha | Syndax Pharma: Two Drug Launches Fuel Transformational Growth (NASDAQ:SNDX) - Seeking Alpha |
| 2026-03-31 | +2.5% | earnings | MarketBeat | Hennion & Walsh Asset Management Inc. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat |
| 2026-03-31 | +2.5% | earnings | MarketBeat | Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $43.00 by Analysts at Mizuho - MarketBeat |
| 2026-04-06 | -2.5% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Syndax Pharmaceuticals (SNDX) Stock Near Support | Price at $24.85, Down 1.19% - Social Trade Signals - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-01-12 | -2.5% | legal | SEC EDGAR | SNDX 8-K: 2.02 and 7.01 (SEC Filing) |
| 2022-11-03 | -2.4% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2023-02-28 | +2.3% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2025-10-31 | +2.2% | earnings | Yahoo Finance | Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance |
| 2026-03-03 | -2.2% | earnings | Seeking Alpha | Syndax Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2024-12-20 | +2.1% | legal | SEC EDGAR | SNDX 8-K: 5.02 (SEC Filing) |
| 2024-02-27 | -2.1% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2023-12-12 | +2.1% | legal | SEC EDGAR | SNDX 8-K: 8.01 and (SEC Filing) |
| 2025-12-17 | -2.0% | news | Seeking Alpha | Syndax Pharma: Continuing Execution In AML |
| 2025-12-17 | -2.0% | news | Seeking Alpha | Syndax Pharma: Continuing Execution In AML (NASDAQ:SNDX) - Seeking Alpha |
| 2026-03-01 | +1.9% | news | Yahoo Finance | Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Yahoo Finance |
| 2026-03-12 | -1.8% | news | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript |
| 2026-04-12 | -1.8% | news | Stock Traders Daily | Liquidity Mapping Around (SNDX) Price Events - Stock Traders Daily |
| 2026-04-11 | -1.8% | legal | Stock Titan | SNDX SEC Filings - Syndax Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2023-02-08 | -1.7% | legal | SEC EDGAR | SNDX 8-K: 5.02 and (SEC Filing) |
| 2021-11-15 | +1.7% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2026-04-19 | -1.7% | news | simplywall.st | Assessing Syndax Pharmaceuticals (SNDX) Valuation After A 110% One Year Return - simplywall.st |
| 2026-04-18 | -1.7% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Syndax Pharmaceuticals (SNDX) Stock: Quarter Start (Modest Uptick) 2026-04-18 - Community Buy Alerts - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-18 | -1.7% | news | Cổng thông tin điện tử tỉnh Lào Cai | Syndax Pharmaceuticals (SNDX) Stock: Quarter Start (Modest Uptick) 2026-04-18 - Retail Picks - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-09-10 | +1.6% | news | Seeking Alpha | Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC |
| 2025-09-10 | +1.6% | expansion | Seeking Alpha | Syndax resumed with Buy at Stifel on newly launched drugs |
| 2025-09-10 | +1.6% | news | Seeking Alpha | Syndax stock resumed with Buy at Stifel (SNDX:NASDAQ) - Seeking Alpha |
| 2025-09-10 | +1.6% | news | Seeking Alpha | Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC (SNDX) - Seeking Alpha |
| 2026-03-22 | -1.6% | news | Motley Fool | This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset |
| 2026-03-21 | -1.6% | news | Motley Fool | High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding |
| 2026-03-21 | -1.6% | news | Motley Fool | This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know |
| 2026-03-21 | -1.6% | news | Motley Fool | This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know |
| 2026-03-21 | -1.6% | news | Motley Fool | Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish |
| 2026-03-21 | -1.6% | news | The Motley Fool | Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish - The Motley Fool |
| 2026-03-21 | -1.6% | news | The Motley Fool | This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset - The Motley Fool |
| 2025-08-18 | -1.6% | analyst | Yahoo Finance | Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals - Yahoo Finance |
| 2025-10-27 | -1.6% | news | Seeking Alpha | Syndax Expands Revuforj Approval, Buy |
| 2025-10-27 | -1.6% | analyst | GuruFocus | SNDX: HC Wainwright & Co. Reiterates Buy Rating for Syndax Pharm - GuruFocus |
| 2026-04-07 | -1.5% | earnings | 富途牛牛 | Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Path To Profitability - 富途牛牛 |
| 2026-04-07 | -1.5% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is Syndax Pharmaceuticals (SNDX) Stock better than industry peers | Price at $24.64, Up 1.44% - Support Bounce - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-07 | -1.5% | news | Cổng thông tin điện tử tỉnh Lào Cai | Is Syndax Pharmaceuticals (SNDX) Stock better than industry peers | Price at $24.64, Up 1.44% - Real Trader Insights - Cổng thông tin điện tử tỉnh Lào Cai |
| 2026-01-14 | +1.2% | news | Yahoo Finance | Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Last Year’s 62.5% Share Price Gain? - Yahoo Finance |
| 2023-07-24 | +1.2% | legal | SEC EDGAR | SNDX 8-K: 8.01 and (SEC Filing) |
| 2024-11-18 | -1.2% | legal | SEC EDGAR | SNDX 8-K: 8.01 and (SEC Filing) |
| 2026-04-02 | +1.2% | news | TipRanks | Syndax Pharmaceuticals Stock Sinks Despite Wall Street Support - TipRanks |
| 2022-02-24 | -1.1% | legal | SEC EDGAR | SNDX 8-K: 5.02 and (SEC Filing) |
| 2025-12-16 | -1.1% | news | Investing.com | Syndax Pharmaceuticals stock hits 52-week high at $21.27 - Investing.com |
| 2023-12-20 | -1.1% | legal | SEC EDGAR | SNDX 8-K: 8.01 and (SEC Filing) |
| 2023-12-15 | -1.0% | legal | SEC EDGAR | SNDX 8-K: 1.01 and (SEC Filing) |
| 2025-09-02 | -1.0% | news | Seeking Alpha | Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript |
| 2022-08-08 | +1.0% | legal | SEC EDGAR | SNDX 8-K: 2.02 and (SEC Filing) |
| 2021-09-15 | +1.0% | legal | SEC EDGAR | SNDX 8-K: 5.02 and (SEC Filing) |
| 2021-12-23 | -0.9% | legal | SEC EDGAR | SNDX 8-K: 1.01, 2.03 (SEC Filing) |
| 2025-08-17 | +0.8% | earnings | Yahoo Finance | BTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, Niktimvo - Yahoo Finance |
| 2026-02-16 | -0.8% | M&A | Yahoo Finance | Why Analysts See Syndax Pharmaceuticals (SNDX) Story Evolving With New Deals And Refined Valuation - Yahoo Finance |
| 2026-03-04 | +0.7% | news | simplywall.st | How Investors May Respond To Syndax Pharmaceuticals (SNDX) Shelf Offering And Revuforj Niktimvo Momentum - simplywall.st |
| 2026-03-04 | +0.7% | news | Yahoo Finance | Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance |
| 2026-03-02 | -0.6% | earnings | simplywall.st | Syndax’s Third FDA Win Accelerates Shift To Multi Product Revenues - simplywall.st |
| 2026-03-02 | -0.6% | news | Finviz | Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Finviz |
| 2025-11-06 | +0.6% | earnings | Seeking Alpha | Syndax Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2025-11-06 | +0.6% | analyst | simplywall.st | Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results - simplywall.st |
| 2022-12-14 | +0.6% | legal | SEC EDGAR | SNDX 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-09-01 | -0.5% | analyst | Yahoo Finance | Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade - Yahoo Finance |
| 2026-03-26 | +0.5% | earnings | Investing.com | Earnings call transcript: Syndax Pharmaceuticals Q4 2025 revenue beats forecast, stock rises - Investing.com |
| 2025-08-06 | +0.5% | news | Yahoo Finance | Citi ups Syndax target, opens ‘upside catalyst watch’ - Yahoo Finance |
| 2026-03-17 | -0.5% | news | Yahoo Finance | Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge? - Yahoo Finance |
| 2025-08-10 | +0.4% | analyst | Yahoo Finance | Analysts Just Made A Dazzling Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - Yahoo Finance |
| 2026-02-25 | +0.4% | earnings | Seeking Alpha | Syndax Pharmaceuticals Q4 2025 Earnings Preview |
| 2025-10-09 | +0.3% | news | Seeking Alpha | Making Money In Biotech Stocks |
| 2022-06-13 | +0.3% | legal | SEC EDGAR | SNDX 8-K: 5.02 and (SEC Filing) |
| 2025-06-26 | +0.3% | legal | SEC EDGAR | SNDX 8-K: 5.02 (SEC Filing) |
| 2025-11-02 | +0.3% | earnings | Seeking Alpha | Syndax Pharmaceuticals Q3 2025 Earnings Preview |
| 2026-03-13 | -0.2% | earnings | Motley Fool | Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment |
| 2026-03-13 | -0.2% | news | Motley Fool | Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned |
| 2026-03-13 | -0.2% | earnings | The Motley Fool | Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment - The Motley Fool |
| 2022-12-05 | -0.2% | legal | SEC EDGAR | SNDX 8-K: 5.02 and (SEC Filing) |
| 2026-04-24 | — | news | GlobeNewswire | Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 |
| 2026-04-24 | — | earnings | Stock Titan | Syndax to post quarterly results April 30, webcast starts at 4:30 p.m. ET - Stock Titan |
| 2026-04-24 | — | earnings | Quiver Quantitative | Syndax Pharmaceuticals to Announce Q1 2026 Financial Results and Business Update on April 30, 2026 - Quiver Quantitative |
| 2026-04-24 | — | news | Sahm | Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 - Sahm |
| 2026-04-24 | — | earnings | Moomoo | Earnings Preview: SNDX to Report Financial Results Post-market on April 30 - Moomoo |
| 2026-04-24 | — | earnings | 富途牛牛 | Earnings Preview: SNDX to Report Financial Results Post-market on April 30 - 富途牛牛 |